期刊文献+

磁共振波谱对前列腺癌的诊断价值 被引量:6

Value of magnetic resonance spectroscopy in diagnose of prostate cancer
下载PDF
导出
摘要 目的探讨三维磁共振波谱(magnetic resonance spectroscopy,MRS)成像在前列腺癌诊断中的应用价值。方法对19例经病理证实的前列腺癌、7例前列腺增生患者进行常规磁共振成像(magnetic resonance imaging,MRI)及增强扫描、MRS检查。增强扫描进行SI-T曲线描记,并将其结果分为三型,将Ⅰ型及Ⅱ型作为慢性前列腺增生的诊断标准,Ⅲ型为前列腺癌的诊断标准。MRS成像计算(cho+cre)/Cit的比值,比值大于0.99为前列腺癌的可疑波谱,将病灶的多体素取平均值,并与病理及其他磁共振方法相对照,比较三者的诊断效能。结果前列腺癌的(cho+cre)/cit比值为2.26±0.52,良性前列腺增生的比值为0.60±0.37,前列腺癌的(Cho+Cre)/Cit值明显高于前列腺增生(P<0.01),与病理结果相对照,MRS对前列腺癌的定性诊断优于磁共振平扫(P<0.05),同样优于增强扫描(P<0.05)。结论MRS对于前列腺癌与非癌组织的鉴别诊断有较高的准确性和特异性,对前列腺癌的诊断有较高的应用价值。 Objective To evaluate the value of magnetic resonance spectroscopy(MRS) in the diagnose of prostate cancer(PCa).Methods Nineteen cases of prostate cancer proved by pathology and seven cases of benign prostate hyperplasia(BPH) were examined by plain,contrast-enhanced MRI and MRS.The results of contrast-enhanced MRI were evaluated by time-signal intensity curves(SI-T curves) and the curves were classified according to PCa or BPH as type Ⅰ、type Ⅱ and type Ⅲ.The SI-T curves of BPH were mainly type Ⅰ and type Ⅱ.Type Ⅲ most appeared in PCa.MRS corresponding(Choline+ Creatine)/Citrate radios were calculated on the basis of the MRS metabolic maps.The case may be PCa if the ratios﹥0.99.The average ratio of multi-voxel was calculated for lesions.All methods were contrasted and evaluated the positive rate of the diagnosis.Results The average ratio of(Cho+Cre)/Cit for PCa(2.26±0.52)was statistically higher than BPH(0.60±0.37)(P〈0.01).Compared with pathology,diagnosis of the cases of PCa by using MRS were better than the cases by using MRI(P〈0.05),so and the results of contrast-enhanced MRI(P〈0.05).Conclusion MRS has high accuracy and specificity for the differential diagnosis of PCa and BPH,and be of high application value for the diagosis of PCa.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2010年第2期171-173,176,共4页 Journal of Harbin Medical University
关键词 前列腺癌 磁共振成像 波谱 prostate cancer magnetic resonance imaging spectroscopy
  • 相关文献

参考文献10

  • 1Reeves GK,Bend V,Bull D,et al.Estimating relative survival among people registered with cancer in England and Wales[J].Br J Cancer,1999,79(1):18-22.
  • 2孙颖浩.我国前列腺癌的研究现状[J].中华泌尿外科杂志,2004,25(2):77-80. 被引量:354
  • 3倪新初,沈钧康,陆之安,钱农,周丽娟,杨晓春,王灌忠,张彩元,王水珍,项剑波,潘昌杰,荣伟良,陈建国南京医科大学附属常州市第二人民医院泌尿外科,单玉喜,钱铭辉.前列腺癌与良性前列腺增生症的MR动态增强与血管生成的相关性研究[J].中华放射学杂志,2005,39(1):54-59. 被引量:51
  • 4王霄英,周良平,丁建平,李飞宇,山刚志,肖江喜,蒋学祥.RS对中国人前列腺癌鉴别诊断标准的初步研究[J].中国医学影像技术,2004,20(8):1150-1153. 被引量:97
  • 5王霄英,高玉洁.前列腺癌的MR诊断[J].实用肿瘤杂志,2002,17(4):223-225. 被引量:9
  • 6Mirowitz SA,Brown JJ,Heiken LP.Evaluation of the prostate and prostatic carcinoma with gadolinium-enhanced endorectal coil MR inaging[J].Radiology,1993,186(1):153-157.
  • 7Bartolozzi C,Croceui L,Menchi I,et al.Endorectal magnetic resonance imaging in local staging of prostats carcinoma[J].Abdom Imaging,2001,26(2):111-122.
  • 8Deering RE,Bigler SA,Brown M,et al.Microvascularity in benigh prostatic hyperplasia[J].Prostate,1995,26(3):111-115.
  • 9Kurhanewicz J,Vigneron DB,Males RG,et al.The prostate:MR imping and spectroscopy.Present and future[J].Radiol Clin North Am,2000,38(1):115-138.
  • 10Ackerstaff E,Pflug BR,Nelson JB,et al.Detection of increased choline compounds with proton nuclear magnetic resonance spectrescopy subsequent transformation of prostatic epithelial cells[J].Cancer Res,2001,61(9):3599-3603.

二级参考文献22

  • 1[1]Kurhanewicz J, Vigneron DB, Hricak H, et al. Three-dimensional H-1 MR imaging of the in situ human prostate with high (0.24-0.7 cm3) spatial resolution[J]. Radiology, 1996, 198(3): 795-805.
  • 2[2]Cornud F, Flam T, Chauveinc, et al. Extraprostatic spread of clinically localized prostate cancer: factors predictive of pT3 tumor and of positive endorectal MR imaging examination results[J]. Radiology, 2002, 224(1): 203-210.
  • 3[5]Bartolozzi C, Crocetti L, Menchi I, et al. Endorectal magnetic resonance imaging in local staging of prostate carcinoma[J]. Abdom Imaging, 2001, 26(2): 111-122.
  • 4[6]Lowry M, Liney GP, Turnbull LW, et al. Quantification of citrate concentration in the prostate by proton magnetic spectroscopy: zonal and age-related differences[J]. Magn Reson Med, 1996, 36(3): 252-358.
  • 5[7]Kurhanewicz J, Swanson MG, Wood PJ, et al. Magnetic resonance imaging and spectroscopic imaging: improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials[J]. Urology, 2001, 57(suppl 4A): 124-128.
  • 6[8]Hahn P, Smith ICP, Leboldus L, et al. The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra[J]. Cancer Research, 1997, 57(6): 3398-3401.
  • 7[9]Schiebler ML, Tomaszewski JE, Bezzi M, et al. Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings[J]. Radiology, 1989, 172(1): 131-137.
  • 8[10]Muramoto S, Uematsu H, Kimura H, et al. Differential of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging[J]. Euro J Radio, 2002, 44(1): 52-58.
  • 9Parker GJ,Suckling J,Tanner SF,et a1.Probing tumor microvascularity by measurement,analysis and display of constrast agent uptake kinetics.J Magn Reson Imaging,1997,7:564-574.
  • 10Kuhl CK,Mielcareck P,Klaschik S,et a1.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions?Radiology,1999:211:101-110.

共引文献496

同被引文献43

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部